Saturday, 25 August 2018



      TOP MISCONCEPTION OF CLINICAL PHARMACY



MISCONCEPTION-1

PHARMACISTS ARE THE MEDS POLICE

Doctors some of the time see drug specialists as guards, preventing patients from getting their required solutions. The Pharmacy and Therapeutics advisory group takes a gander at the clinical utility of meds before taking a gander at costs. Comprehend that if a drug specialist says 'no' to a pharmaceutical it isn't on account of they appreciate it, but since there are bigger cost and viability issues affecting everything.

MISCONCEPTION-2

PRESCRIPTIONS CAN BE WRITTEN AND RE-WRITTEN

WITHOUT CONSEQUENCE
A few doctors assume marked requests can be changed effectively. On the off chance that you sign a request, acknowledge there is a possibility the patient may really get that medicine, regardless of whether the request is composed mistakenly. Be watchful when marking orders; in the event that you have to drop a solution that was sent to an outpatient drug store, call the drug store.

MISCONCEPTION-3

PHARMACISTS ONLY COUNT PILLS

Doctors at times think drug specialists simply apportion solutions. As a general rule, they twofold check measurement, tranquilize, course, recurrence, and so on before apportioning a solution. In the event that you are composing a non-standard request that you know the drug store will probably see is unusual, caution the drug specialist initially to spare them from contacting you.

MISCONCEPTION-4

PHARMACISTS CAN NEVER WRITE PRESCRIPTIONS

Doctors here and there figure drug specialists can't compose remedies or doubt drug specialists' capacities to do as such. In a few associations and in specific circumstances, it is inside the drug specialist's extent of training to compose medicines. Realize this is a piece of the drug specialist part.

MISCONCEPTION-5
PHARMACISTS CAN’T SPECIALIZE

Doctors frequently don't perceive that drug specialists have claims to fame. Like doctors, there are a wide cluster of fortes drug specialists can seek after and their aptitude will be diverse relying upon their claim to fame. Perceive that the forte of the drug specialists you experience matters, and make utilization of their specific aptitude.

MISCONCEPTION-6
Outsourcing won’t work at our facility because our patients are different.

All doctor's facilities are extraordinary and all patients have distinctive requirements. A decent drug store administration organization has stretched out assets to tailor to the necessities and significant regions of worry of every healing facility, regardless of how "unique" it might be. Specifically, littler merchants are frequently less demanding to work with as they are more lithe and can adjust particular answers for every customer.

MISCONCEPTION-7

We will lose our GPO and wholesaler discounts because we will have to use the outsourcing company’s vendors.

With the right partner, you can keep your GPO and all wholesaler discounts intact. In addition, a pharmacy management company will likely have greater reach and additional discounts that you can take advantage of as a client.

MISCONCEPTION-8

The outsourcing company will require our pharmacy staff to sign non-compete clauses making it difficult for us to cancel our agreement.

A few sellers may consider this to be an approach to "snare" a customer and make it hard to drop. At CompleteRx, we work with our customers and potential customers to think of an assention that guarantees we are giving awesome esteem and benefit, and convey on the investment funds we guarantee, without snaring any staff to a non-contend proviso.
By working with an accomplished drug store administration organization and trusting to outsource this office, doctor's facilities can keep on focusing on conveying ideal patient care and containing costs, in the midst of the regularly changing social insurance advertise and anticipated twofold digit medicate cost increments. On the off chance that you'd get a kick out of the chance to take in more about Complete Rx administrations and how we can be the correct accomplice for you, get in touch with us today.

 

Monday, 16 July 2018

Tuesday, 26 June 2018

More and more excited opportunities available at Tokyo, Japan. Book your slots as . Submit your proposal today!!!!
We proudly announces 5th Annual Congress on & scheduled in November 16-17, 2018 at ,


Conference Series LLC Ltd  is a renowned organization that organizes highly notable conferences throughout the globe. Currently we are bringing forth “5th Annual Congress on Clinical & Hospital Pharmacy” (Clinical Pharmacy Congress 2018) scheduled to be held on November 16-17, 2018 at Tokyo, Japan. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Pharmaceuticals and Clinical Research.
https://clinicalpharmacycongress.pharmaceuticalconferences.com/

Friday, 11 May 2018

Development of clinical pharmacy services at King Khalid University Hospital and its impact on the quality of healthcare provided


Clinical pharmacy is a unique service provided by the leading pharmacy departments in the United States. The concept of clinical pharmacy evolved after the significant increase in number of pharmaceuticals in the market and the increasing potential of drug interactions. However, the clinical pharmacists are not merely the individuals who advise on the drug interactions. There are number of functions which include but not limited to; design of appropriate drug therapy, pharmacokinetics assessment and evaluation to optimize drug therapy, drug information dissemination to the physicians and other healthcare providers and participate as toxicology consultant in poison management. At King Khalid University Hospital (KKUH), the first clinical pharmacy services program began in 1983. The aim of this study is to evaluate the impact of our clinical pharmacy program on the patients’ care as well as its perception by the medical staff that came from different parts of the World. Our clinical pharmacists were asked to record any suggestions or interventions in the form. The forms were all collected at the end of each day and entered into a database for analysis. Each intervention was analyzed in order to assess the merit of the action in terms of the therapeutic, financial and direct cost impact. The study showed a positive impact on the patients’ care as well as on the economy of drugs prescribing. Meanwhile, the service was very much appreciated by the medical staff as well as other healthcare providers.

Hotline calling services of national drug information center in Saudi Arabia


National Drug Information Center has started providing services since January 2013; and started answering public and professional inquires through Ministry of Health Hotline Calling Services (937) since December 2013. Ten on call clinical pharmacist and expert trained pharmacist over 24/7 received calls asking about drug information, through manual documentation system of drug information inquiries. It consisted of type and qualification of caller, type of inquiries, and medications and cost avoidance of expected results of drug related problems sequel of drug information inquires if drug information services did not exist and were not answered using USA model. After 12-months of providing services, the total number of answered calls were 976 calls with 264 (27%) answered calls documented; with 300 answered drug inquires. 60% of inquiries were from the public and 40% were from professionals. The most type of inquiries were about medication identification and dose standardization, followed by drugs in pregnancy, the most medications were asked in both public and professional were antimicrobial. The average costs avoidance per each answered call received was (415.78 USD), and total estimated cost avoidance was (405.801 USD) per year. Hotline calling services of National Drug Information Center is costefficient in Saudi Arabia, it was associated with preventing drug related problems and cost savings per each receiving call. Expanding drug information services with electronic documentation excepted healthcare improvement and better care, better patient outcomes, and reduced costs.

Thursday, 10 May 2018

Managing Drug Dosage in the ICU – is Augmented Renal Clearance what we really want to Know?


Clearance (CL) is often felt to be the most physiologic parameter to describe elimination of substances from the body, and to be an independent parameter. However, there is an intimate relationship between CL, apparent volume of distribution (V) and the rate constant for elimination (K), in which CL = V times K, K = CL/V, and V = CL/K. Clearly none is independent. If one looks at general ways of describing similar systems, radioactive decay for example, there is no V, and K is the parameter giving accurate information about disappearance. In general, one can describe the behavior of a system as amount in a compartment, and the rate of movement from one compartment to another in terms of rate constants K. Observations of concentrations can be made as amount/V. CL is never needed. Further, since CL = KV, and since K has units of 1/time and V has units of volume, the units of CL are volume/time, and the actual information of rate of movement of drug becomes obscured when CL is used. However, V and K each give direct information about drug behavior. CL is not needed at all. CL is an unnecessary parameter. Further, since unstable ICU patients often have both rapidly changing renal function and unstable fluid balance at the same time, CL comingles and obscures the information of V and K, while V and K carry the needed information directly. This also facilitates separation of the two clinical issues of fluid balance and drug dosage for optimal management of these separate problems. Further, since ICU patients are so often unstable, conventional software for analyzing data of therapeutic drug monitoring (TDM) is no longer very useful, as it assumes that all the patent’s pharmacokinetic (PK) parameters are fixed and unchanging over the period of the data analysis. However, the interacting multiple model (IMM) algorithm developed in the aerospace community for tracking hostile targets most precisely has been developed [1] and implemented in the Bestdose clinical software [2] specifically to deal with this clinical situation. It tracks gentamicin and vancomycin in post-cardiac surgical ICU patients better than other methods [3]. It tracks changes in V and K as each new data point becomes available, resulting in the most recent Bayesian posterior parameter distributions. These then provide the foundation for dosage regimens to achieve desired target drug concentrations in the near future with maximum precision, using multiple model (MM) dosage design [4]. Illustrative clinical cases will be presented and discussed.

Coffee consumption: A genetic approach


Coffee is among the most widely consumed beverages in the World. Coffee consumption has been receiving a lot of attention in regards to its potential health benefits and risks as well. Caffeine, polycyclic phenols such as chlorogenic acids are some of the most studied constituents from coffee. It has been attributed to various properties to those compounds such as central nervous system stimulant and antioxidants respectively. Coffee is in fact a very complex mixture that varies according with the origin of the beans and roasting process. A new approach to look into possible effects of drugs is through genetic and genomic studies. Actually, it was recently created The Coffee and Caffeine Genetics Consortium with the purpose to identify DNA loci associated with habitual coffee consumption. The technique utilized is called genome-wide meta-analysis (GWMA). This seminar intends to briefly review the results obtained so far. Following the presentation of this seminar, we will open a workshop that will focus in 3 main areas of interest: • Pharmacogenomics of coffee consumption • What’s inside a cup of coffee? • Epidemiology of coffee consumption

BP-C1 in treatment of metastatic breast cancer: A randomised, double blinded and placebo controlled clinical study


Aim: The aim was to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cisdiammineplatium (II) (BP-C1) versus equal looking placebo in treatment of metastatic breast cancer patients. Material & Methods: A randomized, double blind, placebo controlled multi-center study was performed with semi-cross-over design. Patients allocated to placebo switches to BP-C1 after 32 days of treatment. Thirty patients were given daily intramuscular injection of 0.035 mg/kg bw BP-C1 or placebo in 32 days. Biochemistry, hematology, NCI Bethesda (CTC-NCI), EORTC QOL-C30 & BR23 recorded at screening and after every 16 days of treatment. CT performed at screening and every 32nd day. Results: The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in placebo. The increase in the placebo group was significant (p=0.013) but not in BP-C1. The difference between the group was significant in favor of BP-C1 (p=0.04). Significant difference (p=0.026) in favor of BP-C1 regarding RECIST classification. CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group, but significantly in placebo (p=0.05). “Breast cancer related pain and discomfort” and “Breast cancer treatment problem last week” were significantly reduced (p=0.02) in the BP-C1 group and slightly increased in placebo. Significant difference in favor of BP-C1 (p=0.05). “Breast cancer treatment problem last week” was significantly reduced in the BP-C1 group (p=0.02) and slightly increased in placebo. “Breast cancer related pain and discomfort”. Conclusion: BP-C1 reduces the cancer growth, is well tolerated, improves quality-of-life and has few mainly mild AE in patients suffering from stage IV MBC.

Pharmacodynamic Profiling of Antibiotics Used in the Treatment of MRSA-Infected ICU Patients

Background: Appropriate initial treatment choices for methicillin resistant Staphylococcus aureus (MRSA) infections are very critical especially in the intensive care units (ICU) settings. The aim of this study was to compare the ability of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin to achieve their requisite pharmacokinetic/pharmacodynamic (PK/PD) targets against MRSA isolates collected from ICU settings. Methods: Monte Carlo Simulations were performed to simulate the PK/PD indices of the investigated antimicrobials. Probability of target attainment (PTA) was estimated at MIC values ranging from 0.03-32 μg/ml to define the PK/PD susceptibility breakpoints. Cumulative fraction of response (CFR) was computed using MIC data from the Canadian National Intensive Care Unit (CAN-ICU) study. Results: Analysis of the simulation results suggested the breakpoints of 8 μg/ml for ceftobiprole, 0.12 μg/ml for dalbavancin, daptomycin and tigecycline, and 1 μg/ml for linezolid and vancomycin. The estimated CFR were 100, 100, 70.8, 87.6, 88.7, 82.4, 89.4, 98.3 % for ceftobiprole, dalbavancin, daptomycin (4mg/kg/day), daptomycin (6mg/kg/day), linezolid, tigecycline, vancomycin (1gm BID) and vancomycin (1.5gm BID), respectively. Conclusions: Ceftobiprole and dalbavancin have the highest probability of achieving favorable outcome against MRSA infections in the ICU. The susceptibility results suggested a further reduction of the vancomycin breakpoint to 1 μg/ml. Keywords: MRSA, Monte-Carlo simulation, ceftobiprole, dalbavancin, vancomycin

Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis


Abstract

Rheumatoid arthritis patients have a high level of pro-inflammatory interleukin-1. Augmenting the blockade of interleukin-1 receptors by external interleukin-1 receptor antagonist modifies the progression of the disease. Therefore, the aim of this study was to evaluate the clinicalefficacy and safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis. Clinical trials and extension studies that compared anakinra with placebo or other medications were included. Electronic bibliographic databases: PubMed, Scopus, and Web of Sciences were searched from inception to November 2017. The American College of Rheumatology 20% (ACR20) improvement was the primary efficacy outcome measure. Total number of adverse drug events, serious adverse drug events, total treatment withdrawals, and treatment-related withdrawals were safety outcome measures. Ten studies were included in this review. One study did not fulfil quantitative criteria and was assessed qualitatively. Six clinical trials and three extension studies were included in meta-analysis. Patients treated with anakinra are 42% more likely to have ACR20 response than patients without IL-1Ra (pooled RR 1.42; 95% CI 1.01, 2.00). Patients on 30-150 mg anakinra have lower Health Assessment Questionnaire (HAQ) score than patients without IL-1Ra (SMD - 0.28; 95% CI - 0.53, - 0.03). The inflammatory marker erythrocyte sedimentation rate (ESR) was significantly lower among patients treated with 30-150 mg anakinra (SMD - 0.44; 95% CI - 0.65, - 0.23). Patients on anakinra have a 34% more risk of treatment-related withdrawal than placebo. The other parameters were not found to be statistically significant. Anakinra has a significant improvement in ACR20, HAQ, and ESR. The ACR20 response is maintained after 48 weeks of treatment. Anakinra shows higher episodes of treatment-related withdrawals than placebo

Saturday, 28 April 2018

In vivo and in vitro investigation of anti-inflammatory and mucus-regulatory activities of a fixed combination of thyme and primula extracts


Abstract

Hypersecretion of viscous mucus is one of the hallmark symptoms of acute and chronic bronchitis and typically develops secondary to an inflammation of the airway epithelium. Bronchipret® TP film-coated tablets (BRO), an herbal medicinal product containing a fixed combination of thyme herb and primula root extracts, has been successfully used clinically for the treatment of acute bronchitis for more than two decades. However, the underlying pharmacological mechanisms of action have not been fully understood so far. We investigated the anti-inflammatory and mucus-regulatory effects of orally administered BRO in an animal model of pulmonary inflammation that was experimentally induced by intratracheal LPS instillation. BRO was administered once daily for up to three days following the induction of inflammation. Treatment with BRO effectively inhibited polymorphonuclear cell influx into the lung as well as the increase in Mucin 5ac (Muc5ac) protein. Furthermore, the LPS-induced increase of goblet cell numbers was significantly attenuated by BRO treatment. Subsequent in vitro investigations with IL-13 stimulated human primary respiratory epithelium and the Calu-3 respiratory epithelial cell line in air-liquid-interface culture confirmed the effects on mucus production and goblet cell numbers observed in the in vivo studies. They further suggest that the reduction of Muc5ac protein secretion by BRO is associated with reduced Muc5ac mRNA expression as assessed by quantitative Real-Time PCR. Our studies provide evidence that BRO exerts both anti-inflammatory and mucus-regulatory activity and that BRO's effect on mucin production is partially independent from its anti-inflammatory activity. These results contribute to the understanding of the modes of action underlying the clinical efficacy of BRO in acute bronchitis patients.

5th Annual Congress on Clinical Pharmacy & Pharmacology: Altered cytokine profile under control of the sero...

5th Annual Congress on Clinical Pharmacy & Pharmacology: Altered cytokine profile under control of the sero...: Altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms Abstract ...

Altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms


Abstract

The aim of this study is to assess a potential mechanism by which the serotonergic system can control the expression and activity of cytochrome (CYP) 2C11 and CYP3A isoforms during liver insufficiency. A rat model of diethylnitrosamine (DEN)-induced liver insufficiency was developed by administering 50 mg/kg of DEN twice a week for 7 weeks. Dysfunction of the serotonergic system was evoked by feeding the rats with a tryptophan-free diet for three weeks. Dysfunction of the serotonergic system during liver insufficiency decreased the level of proinflammatory cytokines (TGF-β and IL-1β) and increased the level of an anti-inflammatory cytokine (IL-4). Simultaneously, activation of the repressive mechanism IL-4/JAK1/STAT6/SOCS1 of the JAK2/STAT5b-mediated signal transduction pathway and the pERK1/2/GR/STAT6 signal transduction pathway resulted in the suppression of the CYP2C11 and CYP3A isoforms Moreover, dysfunction of the serotonergic system during liver insufficiency equalized the level of testosterone to the basal level, did not change the steady state of the corticosterone level and significantly enhanced the reduced level of growth hormone. An altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms during liver insufficiency through mechanisms based on posttranscriptional and posttranslational processes.

KEYWORDS:

Cytochrome P450; Cytokines; Gene expression; Hormones; Nervous system; Serotonin receptor


Structural elements of stromal interaction molecule function


Abstract

Stromal interaction molecule (STIM)-1 and -2 are multi-domain, single-pass transmembrane proteins involved in sensing changes in compartmentalized calcium (Ca2+) levels and transducing this cellular signal to Orai1 channel proteins. Our understanding of the molecular mechanisms underlying STIM signaling has been dramatically improved through available X-ray crystal and solution NMR structures. This high-resolution structural data has revealed that intricate intramolecular and intermolecular protein-protein interactions are involved in converting STIMs from the quiescent to activation-competent states. This review article summarizes the current high resolution structural data on specific EF-hand, sterile α motif and coiled-coil interactions which drive STIM function in the activation of Orai1 channels. Further, the work discusses the effects of post-translational modifications on the structure and function of STIMs. Future structural studies on larger STIM:Orai complexes will be critical to fully defining the molecular bases for STIM function and how post-translational modifications influence these mechanisms.

KEYWORDS:

Coiled-coil; EF-SAM; Glutathionylation; Glycosylation; Phosphorylation; STIM1; STIM2; Solution NMR; Stromal interaction molecule; X-ray crystallography

Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.


Abstract

Rather than by directly focusing on the ever-changing ALK mutants, here we report an alternative strategy to overcome the drug resistance caused by treatment of ALK inhibitors by developing ALK and Hsp90 dual targeting inhibitors. Since Hsp90 is a molecular chaperone that regulates the maturation, activation and stability of numerous "client proteins" including ALK, dual targeting ALK and Hsp90 may bring more benefits and efficacy against drug resistance of ALK inhibitors. By using our previously developed ALK inhibitor 6 and the clinical Hsp90 inhibitors AUY922 or AT13387 as the templates, we developed several series of resorcinol tethered 2,4-diaminopyrimidines as ALK/Hsp90 dual inhibitors bearing various linkers at different linking sites. Compound 10h and 10j showed high potency against ALK (17.3 vs 9.8 nM) and Hsp90α (100 vs 40 nM). They also have high potency against ALK resistant mutants, especially the gatekeeper mutation ALKL1196M. Both compounds showed strong antiproliferative activity against the ALK-addictive H3122 cells (11 vs 13 nM). The dual functioning mechanism is further confirmed by their down-regulation of the Hsp90 clients ALK and AKT, and up-regulation of the chaperone protein Hsp70 in H3122 cells.

Wednesday, 11 April 2018

Clinical Efficacy of a Dual Action, Topical Anti-edematous and Anti-inflammatory Device for the Treatment of External Hemorrhoids

Abstract

Objective: External hemorrhoids are enlarged, bulging blood vessels in and around the anus and lower rectum. They associate several pathologies such as engorged, edematous and inflamed sinusoids, with numerous proinflammatory cytokines on their surface, requiring a multi-target therapeutic approach. In the absence of any effective treatment, we assessed a newly conceived osmotically active, hypertonic, filmogen solution (Pileseptine-e) directed at attracting hypotonic liquid and helping suppress inflammation. The clinical efficacy and safety of Pileseptine-e on external hemorrhoids was evaluated in this study.
Methods: A 2-week treatment + 1-week follow-up, comparative, randomized, double blind, clinical trial with Pileseptine-e (n=37, test product) versus saline spray (n=17, placebo) was performed in patients suffering from external hemorrhoids. Test and placebo products were applied as 3-4 sprays, 3-4 times per day, for 14 consecutive days. Parameters were evaluated employing a 0-4 or 0-10 scoring scale, before treatment (baseline, T0), 2h after 1st treatment, and on Days 2, 3, 8, and 14, with follow-up check on Day 21.
Results: The test product induced an instant and strong outward exudation of liquid from inside the edematous hemorrhoids, thereby cleaning their surface, keeping it hydrated, and reducing pain and itching. A strong reduction in the size of hemorrhoids and rectal bleeding was also observed, which improved the quality of life of the patients considerably. The placebo product also provided noticeable symptomatic relief, but without effect on the size of hemorrhoids. No adverse effects were observed in any patient.
Conclusion: Reducing edema to allow hemorrhoidal volume to regress, and to normalize the structural physiology of the anal area, is the primary prerequisite to treat external hemorrhoids. Pileseptine-e is an antiedematous, cleaning, hydrating, safe and non-irritant filmogen solution that represents great advancement in the treatment of external hemorrhoids.
Keywords: External hemorrhoids; Filmogen; Osmotic; Antiedematous; Anti-inflammatory solution

Tuesday, 20 March 2018


Clinical Pharmacy Congress is a global annual event to discuss and learn more about Clinical Pharmacy and Pharmacology. The conference aims to bring together leading academic scientists, researchers, and research scholars to exchange and share their experiences and research results on all aspects of Clinical Pharmacy as well as Pharmacology. It also provides a premier interdisciplinary platform for researchers, practitioners, and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Clinical Pharmacy.

In the light of this theme, the Conference series aims to provide a forum for international researchers from various areas of clinical research, hospital pharmacy, method development and validation by providing a platform for critical analysis of new data, and to share latest cutting-edge research findings and results about all aspects of Hospital and Clinical Pharmacy.

Target Audience:
  • Experts in Clinical Pharmacy and Pharmacology
  • Research Heads from Research Centre’s
  • Pharmacists and Pharmacy Technicians from various areas
  • Eminent Scientific Professionals in Pharma
  • Pharmaceutical Associations and Societies
  • Clinical trial experts in Pharmaceutical and Life science
  • Pharmaceutical Business Entrepreneurs
  • Manufacturing Pharmaceutical products Companies
  • Physicians, Nurses, and Clinical Practitioner
  • Noble laureates in Health Care and Medicine
  • Directors of clinical laboratories department in various Universities and institutions
  • Marketing teams of Industries with novel products to showcase at the conference
  • Directors and Professors from Universities and Institutions
  • Post-doctoral and Ph.D. students working on clinical pharmacy and hospital pharmacy program
  • Relevant Graduate and Postgraduate students
Sessions: 
  • Clinical Pharmacology
  • Clinical Pharmacy: Activities and Prescriptions
  • Therapeutic Drug Monitoring
  • Dispensing Pharmacy and Pharma Practice
  • Pharma Medicinal Chemistry
  • Bio pharmaceutics
  • Hospital pharmacy & Health practice
  • Clinical Pharmacy Specialist
  • Veterinary Medicine
  • Drug Dosage and Therapy
  • Clinical Pharmacists
  • Role of Pharmacists & Research in the Hospital
  • Pharmaceutical Toxicology
  • Clinical Drug Development and Therapeutics
  • Oncology Pharmacy
  • Psychiatric Pharmacy
  • Neuropsychopharmacology
  • Pediatric Pharmacy
  • Pharmaceutical Biotechnology
  • Forensic Pharmacy
  • Selective Toxicity 
ConferenceSeries LLC LTD  and its subsidiaries including iMedPub LLC and Conference Series Ltd Organize 3000+ Conferences across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members